Registry for patients with Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry aims to collect clinical information and tumor tissue samples from patients diagnosed with Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG). By establishing a central repository, researchers will gather data on the biology of these tumors to improve diagnosis and treatment methods. The registry will include both newly diagnosed and previously diagnosed patients, allowing for a comprehensive understanding of the disease. Data collected will include clinical, demographic, radiological, and pathological information, facilitating future research collaborations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients of any age (living or deceased) with a diagnosis (either current or past) of a DIPG/DMG tumor
* Unless the patient is deceased, all patients and/or one parent or legal guardian must provide written informed consent as well as HIPAA/release of information consent.

Where it's running

• Cincinnati Children's Hospital Medical Center
  Cincinnati, Ohio, United States Recruiting

Study contacts

• Principal investigator: Trent Hummel, MD — Children's Hospital Medical Center, Cincinnati
• Study coordinator: DIPG/DMG Operations Team
• Email: referrals@dipgregistry.org
• Phone: 1-877-349-8074

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BCB-276 CAR T therapy for DIPG in children and young adults

  This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.

  Recruiting at 3 sites Phase 2 BrainChild Bio, Inc · Los Angeles, California and 5 other locations · NCT07680439

• VRT106 plus radiotherapy in adults with DMG/DIPG

  This trial tests whether adding VRT106 to radiotherapy is safe and could help adults with DMG/DIPG.

  Recruiting Phase 2 Guangzhou Virotech Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07589257

• Combining Atovaquone with Radiation for Treating Children's Brain Tumors

  This study is testing if adding atovaquone to radiation therapy can help children with aggressive brain tumors feel better and improve their treatment outcomes.

  Recruiting at 2 sites Phase 1 Emory University · Atlanta, Georgia and 1 other locations · NCT06624371

• Treatment of high-grade glioma in young patients using olutasidenib and temozolomide

  This study is testing if a new combination of olutasidenib and temozolomide can help young patients with high-grade gliomas that have a specific mutation feel better after their radiotherapy.

  Recruiting at 8 sites Phase 2 Rigel Pharmaceuticals · Aurora, Colorado and 19 other locations · NCT06161974

• Combining ribociclib and everolimus for treating high-grade gliomas in young patients

  This study is testing if a combination of two drugs, ribociclib and everolimus, can help young patients with high-grade gliomas live longer and feel better after their initial treatment.

  Recruiting at 12 sites Phase 2 Nationwide Children's Hospital · Aurora, Colorado and 19 other locations · NCT05843253

• Genetic profiling for pediatric high-grade glioma treatment eligibility

  This study is testing if genetic testing of brain tumors in children and young adults with high-grade gliomas can help match them to the best treatment options.

  Recruiting at 13 sites Nationwide Children's Hospital · Aurora, Colorado and 21 other locations · NCT05839379

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.